Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Ovascience Inc. (NASDAQ: OVAS).

Full DD Report for OVAS

You must become a subscriber to view this report.


Recent News from (NASDAQ: OVAS)

OvaScience reports Q1 results
OvaScience (NASDAQ: OVAS ): Q1 EPS of -$0.21 More news on: OvaScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:45
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
OvaScience SM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update. OvaScience is completing preclinical ...
Source: Business Wire
Date: May, 03 2018 16:01
OvaScience's (OVAS) CEO Christopher Kroeger on Q4 2017 Results - Earnings Call Transcript
OvaScience, Inc. (OVAS) Q4 2017 Earnings Conference Call March 15, 2018 4:30 PM ET Executives Jennifer Viera - Investor Relations Christopher Kroeger - Chief Executive Officer Jonathan Gillis - Senior Vice President, Finance Analysts Eliana Merle - Credit Suisse Presenta...
Source: SeekingAlpha
Date: March, 15 2018 19:00
OvaScience beats by $0.04, misses on revenue
OvaScience (NASDAQ: OVAS ): Q4 EPS of -$0.24 beats by $0.04 . Revenue of $0.09M (-25.0% Y/Y) misses by $0.1M . Press Release More news on: OvaScience, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 15 2018 16:04
OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial – – Appointed James Lillie, Ph.D. as Chief Scientific Officer to...
Source: Business Wire
Date: March, 15 2018 16:01
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OvaScience SM , Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James...
Source: Business Wire
Date: March, 12 2018 16:02
OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m. ET on Thursday, March 15, 2018 to discuss f...
Source: Business Wire
Date: March, 08 2018 16:02
Finding Biotech Value In All-Time Highs
Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes...
Source: SeekingAlpha
Date: February, 10 2018 00:56
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018
NEW YORK, NY / ACCESSWIRE / January 22, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against OvaScience, Inc. (OVAS) ("OvaScience" or the "Company") (NASDAQ: OVAS) and certain of its officers, on behalf of shareholders who purchas...
Source: ACCESSWIRE IA
Date: January, 22 2018 10:30
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018
NEW YORK, NY / ACCESSWIRE / January 19, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against OvaScience, Inc. (OVAS) ("OvaScience" or the "Company") (NASDAQ: OVAS) and certain of its officers, on behalf of shareholders who purchas...
Source: ACCESSWIRE IA
Date: January, 19 2018 10:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-220.94610.94610.950.933758,654
2018-05-210.94610.9470.960.93391,425
2018-05-180.930.950.960.9347,724
2018-05-170.940.94470.9580.9301107,900
2018-05-160.930.93060.95730.9398,670

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-228524,4580.3475Cover
2018-05-2131,90655,15957.8437Short
2018-05-185,00022,54422.1789Cover
2018-05-1727,93843,08364.8469Short
2018-05-165,19539,26813.2296Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OVAS.


About Ovascience Inc. (NASDAQ: OVAS)

Logo for Ovascience Inc. (NASDAQ: OVAS)

OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company s patented technology is based on the discovery of egg precursor cells EggPCSM , which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization IVF . OvaScience s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.

 

Contact Information

 

 

Current Management

  • Michelle Dipp / CEO, President
  • Alison Lawton / COO
  • Theresa McNeely / Chief Comm. Officer
  • Christopher Bleck / Corp. Commun.
  • Michael Silver / Senior Operations Manager

Current Share Structure

  • Market Cap: $33,241,480 - 05/11/2018
  • Issue and Outstanding: 35,758,907 - 04/30/2018

 


Recent Filings from (NASDAQ: OVAS)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 03 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (NASDAQ: OVAS)

Daily Technical Chart for (NASDAQ: OVAS)


Stay tuned for daily updates and more on (NASDAQ: OVAS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: OVAS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OVAS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of OVAS and does not buy, sell, or trade any shares of OVAS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/